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INTRODUCTION
Premature birth is the most important cause of perinatal death and long term
morbidity in the world today. Although an increasing proportion of premature births
are induced secondary to pre-existing fetal and maternal conditions, over half of
these deliveries are due to spontaneous onset of uterine contractions (spontaneous
preterm labour). So far, our ability to successfully treat women whose pregnancies are
complicated by preterm labour is hampered by a lack of knowledge of the endocrine
and biochemical factors that initiate human parturition.
The human uterus is a smooth muscle organ which undergoes considerable
distension during gestation without expelling its contents. It is not clear what
regulates this state of relative quiescence. During labour, the uterus contracts in a
regular and coordinated fashion to forcibly expel the fetus. Contraction in smooth
muscle tissues is regulated by two key enzymes: calcium-calmodulin dependent
myosin light chain kinase (MYLK) which phosphorylates the regulatory 20 kDa
myosin light chain (MYL) to generate increases in tension and contraction, and
a trimeric protein phosphatase called myosin phosphatase (MLCP) which induces
a state of relaxation through dephosphorylation of activated MYL.1 Therefore the
force of contraction and MYL phosphorylation in the uterus during labour is
determined by the equilibrium between MYLK and MLCP (Figure 1). The mechanisms
that regulate these two enzymes in the human uterus remain poorly under-
stood.
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Figure 1 Myosin equilibrium in smooth muscle cells
Smooth muscle contraction is determined by level of myosin (MYL) phosphorylation which is determined
by the two enzymes myosin light chain kinase (MLCK) and myosin phosphatase (MLCP). Calcium (Ca2+)
bound calmodulin activates MLCK which phosphorylates MYL to cause contraction. MLCP is a trimeric
phosphatase which dephosphorylates activated myosin (MYL-P) to induce a state of relaxation. RHO and RND
proteins modulate the RHO Kinase-MLCP axis via mechanisms which are independent of intracellular calcium
levels.
THE RHO PROTEIN FAMILY
RHO (Ras homology) guanosine triphosphatases belong to the RAS super family
of guanosine triphosphate (GTP) binding proteins. They function as molecular
switches which regulate a wide variety of cellular functions ranging from membrane
trafficking, gene transcription, actin polymerization and smooth muscle contraction.
The mammalian RHO family is made up of at least 10 different proteins namely
RHO gene family members A, B, C and D (RHOA, RHOB, RHOC, RHOD); RHO
family GTPase 1–3 (RND1–3); RAS related protein RAC1–2; cell division cycle 42
GTP binding protein (CDC42); RHO gene family member F in filopodia (RIF) also
known as RHOF; RHO gene family member Q (RHOQ) also known as TC10 and
ADP-ribosylation factors (ARF1 and ARF6).
RHO protein activity is determined by the levels of protein expression, state of
phosphorylation or prenylation and the subsequent change in subcellular localization.
Activated (GTP bound) RHOA binds to RHO kinase (ROCK) which inhibits the
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regulatory binding subunit of myosin phosphatase and prevents dephosphorylation of
MYL. The increase in MYL phosphorylation and contraction at a constant intracellular
calcium ([Ca2+]i) is termed “Ca
2+ sensitization”.1
Structure and regulation of RHO proteins
RHO proteins usually have between 190 to 250 residues and measure approximately
20 to 30 kDa in size. The RHO core structure includes an effector domain and four
separate nucleotide binding regions which span the length of the core structure. They
have conserved residues at Gly14, Thr19, Phe30 and Gln63 which are required for GTP
binding and hydrolysis. RHO proteins have intrinsically low levels of GTPase activity
and cycle between an active GTP-bound state and an inactive GDP-bound state.
The effector domain (residues 25–28) changes conformation between the GTP bound
and GDP bound states ensuring that only GTP RHO proteins activate downstream
effectors.
RHO activity is controlled by three classes of regulators: guanine nucleotide
exchange factors (ARHGEFs); GTPase activating proteins (ARHGAPs) and guanine
nucleotide dissociation inhibitors (ARHGDIAs). ARHGEFs activate the exchange of
GTP for GDP.2 ARHGAPs reduce the levels of active GTP bound RHO by accelerating
the rate of GTP hydrolysis to yield GDP.3 ARHGDIAs extract prenylated RHO
proteins from membranes and sequester them in the cytosol.4
RND proteins
RND proteins are a subfamily of RAS small GTP-binding proteins made up of
RND1, RND2 and RND3. The name RND (‘round’) is due to their inhibition of
RHOA stress fibre formation and induction of ‘rounded’ cell phenotype in Swiss 3T3
fibroblasts. RND proteins have key structural differences which distinguish them
from other RHO proteins. RND proteins have almost no GTPase activity and exist
in a constitutively active GTP bound state due to serine substitutions at residues 17,
64 and 66 which determine GTPase activity by coordination of magnesium binding
within the nucleotide binding region. RND proteins undergo post translational
modification, i.e. prenylation, by the addition of a 15 carbon group (farnesylation)
in contrast to RHO proteins which are modified by addition of a 20 carbon group
(geranygeranylation).
RND protein activity is determined by the levels of protein expression,
phosphorylation by ROCK and protein kinase C (PRKC) and prenylation. RND
proteins bind to ROCK and inhibit RHOA downstream effects.5 Thus the relative
expression of RHO and RND proteins may determine the overall RHO activity and
function.
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RHO and RND effector interactions
ROCKs have four functional domains: an N terminal kinase domain, a central coiled-
coil domain (CC) which contains a RHO binding domain (RBD) and a C terminal
pleckstrin homology (PH) domain. The kinase domain binds to the PH and RBD
domains to form an auto-inhibitory closed inactive loop. Binding of active GTP bound
RHOA to the RBD leads to auto phosphorylation and disruption of the auto-inhibitory
interaction between the C-terminal PH and RBD domains and the N-terminal kinase
domain. The activated kinase adopts an open conformation that enables it to bind
downstream targets.
RHO and RND proteins bind to different regions on ROCK. RND proteins bind to a
region made up of the first 420 N-terminal amino acids including the kinase domain,
whilst RHO proteins bind to the C terminal RBD sited at the end of the central CC
domain.6 RND proteins optimally bind to RHOA activated ROCK, suggesting that
prior RHOA action is a prerequisite for RND inhibition.
There are two ROCK isoforms with different functions in the placenta and in
the developing fetus. ROCK2 deficient (ROCK2-/-) mice usually die in utero due to
placental dysfunction and fetal growth retardation caused by thrombus formation
in the placenta. ROCK1-/- mice have a different phenotype and usually survive
pregnancy and labour to die postnatally from filamentous actin accumulation leading
to impairment in the closure of the umbilical vein.7 Analysis of ROCK2 null mice
suggests that ROCK1 does not compensate for ROCK2 function.8
RHO AND RND PROTEIN REGULATION OF UTERINE CONTRACTILITY
The force of contraction in uterine smooth muscle cells depends on the level of
MYL phosphorylation resulting from the equilibrium between MLCK and MLCP.
During pregnancy, the myometrial contractile apparatus undergoes several changes
that enable it to adapt to the physiological alterations in size, stretch and tension
due to the growing fetus. These gestational changes prime the myometrium for the
increase in contractile activity required for normal labour. Pregnant myometrium
is more sensitive to the stimulatory effects of calcium mobilising agonists than
non pregnant myometrium. In the rat, pregnant myometrium develops greater
levels of tension at a given level of MYL phosphorylation after stimulation
with a range of agonists including oxytocin, prostaglandins E2 and F2 alpha,
carbachol or high K+9. Tissue strips from pregnant women generate greater levels
of tension at any given level of MYL phosphorylation than strips from non pregnant
women.10,11
The mechanism of the increased myofilament sensitivity to these agonists during
pregnancy has been investigated; treating permeabilised rat myometrial strips with
Ca2+ and calyculin-A (a phosphatase inhibitor) produces similar increases in force in
non pregnant and pregnant myometrial strips.9 This led Kim et al9 to conclude that
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the increase in force generated in myometrial smooth muscle during pregnancy is due
to inhibition of a phosphatase, presumably myosin phosphatase.
The first physiological experiments demonstrating the effect of RND protein on
contraction in smooth muscle tissues were performed by Pacaud’s group.12 They
showed that progesterone and oestrogen increased RND1 content in rat ileal strips.
Elevations in RND1 expression were associated with a reduction in agonist induced
Ca2+ sensitization.12 Furthermore, co-transfection of RHOA and RND1 reversed
RHOA mediated Ca2+ sensitization. The action of RND1 was independent of the level
of intracellular calcium ([Ca2+]i) and did not affect the calcium-force response curve
or the force of contraction generated by the myosin phosphatase inhibitor calyculin
A. Subsequently, other investigators suggested that the increase in steroid hormones
during gestation causes a time dependent increase in RND1 mRNA expression in the
rat uterus.13 RND1 mRNA levels fell to pre-pregnancy levels at day 1 postpartum.
In line with previous observations, Kim et al13 suggested that the increase in RND1
mRNA expression may function to inhibit RHOA Ca2+ sensitization and maintain
uterine quiescence during gestation. The Pacaud laboratory later correlated differences
in RHOA and RND3 expression in rabbit myometrium at mid gestation with a loss of
RHOA mediated Ca2+ sensitization.14 Niiro et al15 highlighted a possible regulatory
role for the RHO proteins in uterine smooth muscle contraction by demonstrating
an increase in ROCK1 and ROCK2 mRNA expression in rat myometrium during
pregnancy.15
Relevance to human myometrium
Our data in humans demonstrates that there is an increase in myometrial RND2
and RND3 mRNA levels during pregnancy (Figure 2). The mRNAs of other RHO
family members namely RHOA and RHOB were also increased. Moreover we noted
a dramatic increase in RND2 and RND3 protein expression in the pregnant groups.16
In contrast RHOA, RHOB and RND1 protein levels did not alter with pregnancy or
labour.
RHO and RND protein function in human myometrium may be determined by their
levels of expression, GTP binding, state of phosphorylation, intracellular localisation
and the activity levels of effector molecules like ROCK1.17 The overarching
hypothesis is that an increase in RHOA and ROCK1 expression may account for
the increased contractile activity at the end of gestation and during labour. Several
investigators have suggested that RHOA and ROCK mRNA and protein expression are
elevated in rat, mouse and human myometrium during pregnancy.15,18–20 However,
while there is evidence that myometrial RHOA, ROCK1 and ROCK2 levels do not vary
between non pregnant, pregnant not in labour, spontaneous labour and spontaneous
preterm labour groups,16 we observed a four-fold increase in GTP RHOA levels in
preterm labour.21
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Figure 2 RHO and RND mRNA and protein expression in non pregnant and pregnant human myometrium
A. RHOA, RHOB, RND2 and RND3 mRNA expression in five individual samples each from non pregnant
(NP) and pregnant non labouring (P) human myometrial tissue. mRNA expression was measured by
quantitative real time RT-qPCR. The total of RHO, RND and RPII mRNA was determined from HeLa
standard curves. The amount of RHO and RND mRNA was normalized to the amount of RNA
polymerase II (RPII) mRNA expression within each sample.
B. Whole tissue homogenates from the samples above were immunoblotted with RHO and RND antibodies.
All the samples were analysed in duplicate and normalized to individual tubulin bands and plotted in a
logarithimic scale within allotted patient groups. The histograms are means and the vertical bars represent
SEM (∗ P <0.001), Student’s t test.
We have also shown that myometrial ROCK activity is elevated after treatment
with a caspase-3 inhibitor which prevents cleavage of ‘active’ p160ROCK1 to
the ‘inactive’ p130ROCK1 form.22 Chronic thromboxane receptor stimulation
with U46619 increased p160ROCK1 expression and these changes were reversed
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by pretreatment with SQ29458, a thromboxane receptor antagonist.22 Agonist
activation of RHOA enhances ROCK activity by increasing the stability of the
p160ROCK1.23
Tonic versus phasic contractions
During labour the uterus contracts in a predominantly phasic manner but also requires
periods of sustained tension (i.e. tonic contraction) in between the phasic contractions.
The physiological relevance of RHO proteins to these forms of contraction is a matter
of considerable debate. Kupittayanant et al24 suggested that ROCK inhibition with
Y-27632 was maximal during tonic rather than phasic agonist- and K+-stimulated
contractions in human myometrial strips. Thus, they concluded that RHOA primarily
regulates the strength of tonic contraction and may not play a significant role in
augmenting the phasic activity in labour.24,25
RHO activation, membrane translocation and myometrial contraction
RHO proteins shuttle between an active GTP- membrane bound form and an inactive
GDP cytosol and presumably ARHGDI sequestered form. Several investigators have
now linked RHO mediated increases in tension and MYL phosphorylation to changes
in membrane bound levels and GTP bound state. Lysophosphatidic acid (LPA) is a
classical RHO agonist that increases MYL phosphorylation in myometrial tissue
strips.18 LPA increases GTP-RHOA levels in human myometrial smooth cells,
suggesting that LPA-induced MYL phosphorylation may in part be due to RHOA
activation.21 These experiments highlighted the potential role of agonist induced RHO
activation of human uterine smooth muscle contraction and MYL phosphorylation
(Figure 3).
One of the key experiments linking G-protein coupled receptor (GPCR) stimulation
to protein translocation in smooth muscle cells was conducted by Taggart
et al.26 The investigators demonstrated that carbachol induced Ca2+ sensitisation
in smooth muscle cells resulted in protein kinase C beta (PRKCB), RHOA and ROCK
translocation to the plasma membrane.26 In order to elucidate the RHO mechanism
that belies the heightened contractility of pregnant myometrial tissue, they explored
the biomechanical coupling of RHO protein activation and the relationship between
force and [Ca2+]i in rat myometrial cells after carbachol stimulation. Carbachol
stimulated increases in the force of contraction and MYL phosphorylation at a
constant [Ca2+]i were reversed by Y27632. The authors concluded that contractile
drugs like carbachol and oxytocin can cause membrane translocation of RHOA in rat
myometrial cells.27
Our demonstration of increased membrane bound RHOA, RHOB, RND2 and
RND3 proteins in pregnant myometrium28 suggests that the changes in myometrial
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Figure 3 ROCK regulation of myosin phosphorylation in smooth muscle cells
Myosin phosphorylation is the principal determinant of smooth muscle contraction. Myosin phosphorylation
is primarily regulated by myosin light chain kinase (MYLK) and myosin phosphatase (MLCP). MLCP is made
up of 3 subunits: myosin binding subunit (MYPT1), protein phosphatise unit (PPP1c) and a 20kDa subunit of
unknown function. ROCKs regulate myosin phosphatase (MLCP) by a variety of mechanisms:
1 ROCK phosphorylates the myosin binding subunit MYPTI at Thr696 and Thr853.62–64 Phosphorylated
MYPT1 inhibits PPP1c activity towards phosphorylated myosin (MYL-P)6].
2 ROCK phosphorylates the protein kinase C (PRKC) dependent phospho-inhibitory protein CPI-17 at
Thr38 which directly binds and inhibits the PPP1c catalytic subunit.65–67
3 ROCK directly phosphorylates MYL at Thr18 and Ser19.68
4 ROCK also phosphorylates death associated protein kinase (DAPK3)69 and integrin linked kinase (ILK)50,70
after activation, further regulating MLCP activity by inhibiting by the MYPT1.71
5 GTP-bound RHOA binds to ROCK which activates a number of actin binding proteins to polymerize
F-actin filaments. Polymerised actin interacts with MYL-P to cause stress fibre formation and smooth
contraction. ERM (ezrin-moesin-radixin) are proteins that link actin filaments to membrane proteins
on the cell surface. The amino and C-terminus of ERM proteins bind to each other to form activated
protein dimers which interact with membrane bound target proteins. ROCK2 phosphorylates moesin at
Thr558, radixin at Thr564 and ezrin at Thr567 to disrupt intramolecular interaction/ dimerisation and
binding of ERM proteins to F-actin filaments.72 Adducin is a filamentous actin binding protein that caps the
fast growing ends of actin filaments and recruits spectrin to the filament ends. ROCK2 phosphorylates
α-adducin, and increases its activity to bind to F actin.73
cell shape, size and function during pregnancy are reflected by alterations in
RHO protein activation. We observed increases in RHOA membrane translocation
under both tension free and isometric conditions in human myometrial tissue
strips after oxytocin and carbachol treatment.29 Curiously, both oxytocin and
carbachol also produced marked increases in RND1 and RND2 membrane
translocation.
There is evidence that agonist stimulation of other GPCRs like the corticotropin
releasing hormone (CRH) type 2 receptor also results in MYL phosphorylation
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and contraction in human myometrial smooth muscle cells. Urocortin (a 38 kDa
corticotrophin releasing hormone neuropeptide) stimulates myometrial cell CRH R2
to increase MYL phosphorylation via a variety of mechanisms which include RHOA
activation and RHO membrane translocation. This was confirmed by RHO inhibitors
like C3 exotoxin and Y-27623 which reversed MYL phosphorylation and RHOA
translocation. In addition, urocortin mediated MYL phosphorylation was abolished by
the PRKCB inhibitor bisindolylmaleimide and the mitogen activated kinase inhibitor
U0126 suggesting that these additional pathways also regulate myometrial cell MYL
phosphorylation and contraction.30
Woodcock et al31,32 have proposed that physiological uterotones such as oxytocin
and PGF2alpha enhance myometrial sensitivity to Ca2+ through a RHOA-ROCK
dependent mechanism31 We have mapped the effects of oxytocin and carbachol
on RHO protein targets downstream of ROCK1. Oxytocin induced tension and
contraction in human myometrial strips under isometric conditions are associated
with concurrent increases in phosphorylation of the myosin phosphatase regulatory
subunit PPP1R12A at Thr696 as well as MYL-Ser19/Thr18 phosphorylation.33
Moreover, pregnancy is associated with a marked up regulation in the expression
of native and activated forms of the PRKCB dependent inhibitory phospho-protein
CPI-17.21,34 There is now evidence that oxytocin can induce changes in CPI-17-Thr38
phosphorylation in stimulated human uterine smooth muscle cells.21
Involvement of RHO proteins in uterine quiescence and abnormal labour
We examined a panel of over 10 RHO GTP binding proteins to determine if changes
in RHO protein expression were associated with contractile activity in spontaneous
labour and preterm labour. RND2 and RND3 levels were markedly up regulated
relative to RHOA levels during gestation. This increase in RND protein expression
correlated with a reduction of ROCK1 inhibitory phosphorylation of the MYPT1
subunit in the pregnant tissues examined.16 These findings are consistent with
the effects of RND proteins in rat and rabbit myometrium and imply that in
humans, RND proteins may regulate the relative quiescence of the uterus during
gestation.
The lack of changes in RND to RHOA ratios in labouring myometrium suggests that
other mechanisms may be important at parturition. RHOB and RHOD are endosomal
GTP binding proteins which regulate actin vesicular dynamics and GPCR trafficking.
Figure 4 shows the localisation of RHOB and RHOD in pregnant tissue sections
and cultured myometrial cells. A down regulation in the expression of RHOD, a
known RHOA inhibitor, may account for the 3 fold increase in GTP RHOA levels
in preterm labour.21,35 The RHOA-RND-RHOD interaction in human labour requires
further investigation. It is not known how progesterone and oestrogen upregulate RND
protein expression during pregnancy. Nevertheless, we have now identified predicted
putative oestrogen and progesterone response elements in human RND genes in a
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Figure 4 Localisation of endosomal RHO proteins RHOB and RHOD in pregnant tissue sections and
cultured myometrial cells.
Panel A
RHOB shows an intense cytoplasmic localization in nonpregnant and pregnant uterine tissue sections (left
and middle panels) and a marked punctuate cytoplasmic, perinuclear and vesicular localization in freshly
dispersed pregnant myometrial cells (right panel).
Panel B
RHOD binds to the cytoplasm of non pregnant and pregnant uterine tissue sections (left and middle panels)
and freshly dispersed pregnant myometrial cells (right panel). RHO protein (red) and actin phalloidin (green)
staining of myometrial fibres (x40 magnification) and cultured myometrial cells (x63 magnification). Nuclear
proteins were detected with DAPI (blue).
quest to elucidate how these pregnancy related hormones regulate RHO and RND
protein function in myometrium and the placenta.
We have noted some interesting changes in RHOA and RND protein function
during dysfunctional labour (defined as spontaneous labour with ‘secondary arrest’
not treated with oxytocin). RHOA membrane levels increased during gestation and in
normal labour at term but were reduced in the dysfunctional labour group (submitted
for publication). This represents attenuation in RHOA activation in dysfunctional
labour relative to normal spontaneous labour. Oxytocin stimulation increases both
RHOA and RND2 membrane translocation therefore it is plausible to suggest that the
use of oxytocin will correct the abnormal RHO function in this sub group.
ADP-ribosylation factor (ARF) GTP binding proteins regulate GPCR receptor
desensitization.36 ARF guanine nucleotide-exchange factors (GEFs) catalyse the
nucleotide exchange on the ARF-GDP bound GPCR complex allowing the receptor to
internalize.37 ARF6 and PSCD3 (an ARF6 GEF) are highly expressed in human placenta
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and myometrium. Recent experiments from our laboratory have found changes in
ARF6 and PSCD3 mRNA and protein expression in preterm myometrium from
women with pre-eclampsia or fetal growth restriction suggesting for the first time
that changes in ARF receptor trafficking may be responsible for serious uterine and
placental complications of pregnancy.38
NOVEL RHO EFFECTOR MECHANISMS DURING PREGNANCY AND IN LABOUR
There are numerous kinases downstream of RHOA-ROCK which regulate smooth
muscle MYL phosphorylation. The complex interaction of all these RHO effectors on
actin and myosin interaction leading to contraction is illustrated in Figure 3.
To date six RHO effectors, ROCK1, ROCK2, diaphanous forming proteins
(DIAPH)1, DIAPH2, p21 protein activated kinase 2 (PAK2) and protein kinase
N1 (PKN1) have been identified in human myometrium.39 ROCKs are the most
characterized RHO family proteins in smooth muscle cells. Although ROCK levels
are not altered with pregnancy or labour, elevated GTP RHOA levels may enhance
ROCK activation and MYL phosphorylation and contraction in labour. Preliminary
investigations have revealed increases in ROCK1 and ROCK2 nuclear localization
in myometrial and interstitial cells during labour.40 Progesterone and oestrogen
regulate the nuclear localisation of some kinases including cyclin dependent kinases
(cdc4)41 and adaptor molecules like CT10 regulator of kinase in uterine smooth
muscle and epithelial cells.42 ROCK also induces nuclear translocation of extracellular
signal-regulated kinases (ERK1/2) in smooth muscle cells.43 Growth factors can
induce ROCK nuclear translocation’. Transforming growth factor b translocates
ROCK2 into the nucleus where it inhibits CDC24 phosphatase to regulate cell cycle
progression.44 The nuclear localisation of ROCK proteins during pregnancy suggests
a role in myometrial cell division and regulation of gene expression. However more
investigation is required to determine if this change in ROCK protein function has
any effect on MLCP activity and myofilament sensitivity to physiological uterotones
like oxytocin and PGF2a in labour.
There is evidence that other RHO effectors in human myometrium may be involved
in uterine function. A constitutively active p34 protein fragment of the RHO effector
PAK2 is elevated in human myometrium during pregnancy.18 Protein kinase N1
(PKN1), the first known RHOA effector to be discovered was also present in our
myometrial samples. Its expression was up regulated in all the pregnant compared
to non pregnant groups. PKN1 expression was mirrored by a similar increase in the
expression and phosphorylation of its downstream target CPI-17.39,45 This represents
another mechanism of Ca2+ sensitization in pregnant myometrial tissue. Thus the
PKN1-CPI-17 and the RHOA-ROCK-RND pathways may converge on MLCP at PPP1c
and MYPT1 sites respectively. Crucially, these pathways can function independently
of each other (Figure 3).
The human diaphanous proteins DIAPH1 and DIAPH2 interact with actin46,47 and
their expression is altered with human labour. The role of actin polymerisation in
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uterine myofilament remodeling during gestation and in priming the contractile
apparatus for labour is not well understood. Thus we do not fully appreciate the
significance of differential signaling of RHO actin effectors in pregnant women.
Other protein kinases can inhibit MLCP activity by phosphorylating MYPT1
at Thr696. Candidate kinases include PAKs,48 DMPKs,49 ILK,50 and ZIPK, now
known as death associated protein kinase 3.51 We used immunoblotting and
immunohistochemistry to characterize DAPK3 expression in human tissue samples.
Preliminary findings indicate that DAPK3 may undergo differential signaling and
activation during labour.52
PHARMACOLOGICAL REGULATION OF THE RHO PATHWAY
ROCK inhibition by pyridine derivatives
Physiological uterotones such as PGF2a and oxytocin activate GPCRs to promote
Ca2+ mobilization and Ca2+ -calmodulin dependent MYLK activation. Moreover these
agonists generate increases in tension at a constant activity of intracellular Ca2+.
We have shown that myometrial GTP RHOA and ROCK activity are elevated during
spontaneous preterm labour.39 Thus it is conceivable that inhibition of ROCK activity
may lead to attenuation of the tension that may be associated with spontaneous
preterm labour.
Several compounds have been manufactured to inhibit ROCK function. The most
widely used N-(4-pyridyl)-4-(1-aminoethyl) cyclohexane carboxamide (Y-27632) is a
highly potent, cell-permeable pyridine derivative which acts as an ATP-competitive
inhibitor with equal potency against ROCK1 and ROCK2.53 Y-27632 inhibits agonist
induced phosphorylation of myosin phosphatase and MYL to disrupt RHOA mediated
stress fibres and cause smooth muscle relaxation.53 However Y-27632 and other
similar compounds like Y-32885 inhibit other related kinases like PRK1 and PRK2
at concentrations required for ROCK inhibition.54 Multi kinase inhibition is also
observed with another ROCK inhibitor compound HA 1077 (AT877 or fasudil
hydrochloride).55,56 Therefore, the potential of ROCK inhibitors may be limited
due to their lack of kinase specificity. Further research is required on the effect of
ROCK inhibitors on myometrial tissue strips during agonist induced and spontaneous
contractions in normal and preterm labour.
Farnesyltransferase and geranylgeranyltransferase regulation of RHO protein
function
Farnesyltransferases and geranylgeranyltransferases catalyse the irreversible addition
of farnesyl to RND proteins; or geranylgeranyl to RHO, RAS, RAC, RAP and
CDC42. Pharmacological inhibition by farnesyltransferase inhibitors (FTIs) and
RHO proteins, pregnancy and labour 295
geranylgeranyltransferase inhibitors prevent isoprenoid modification and block the
lipid mediated association of RAS and RHO proteins with the plasma membrane and
their subsequent binding with downstream targets.57 Other small molecule inhibitors
such as farnesyl thiosalicylic acid compete with the isoprenoid attachment of small
GTPases for membrane binding sites.58,59
Up regulation of RND protein expression during gestation may inhibit RHOA
activity, thereby maintaining uterine quiescence. RND protein inhibitors (FTIs) may
induce labour in conditions such as preeclampsia and fetal growth restriction.
RHO proteins and uteroplacental vascular function
RHO proteins have been implicated in a range of vascular smooth muscle disorders
including hypertention, arterioscleriosis and also directly in ischaemic myocardial
damage. ROCK inhibitors have been used in animal models of cardiovascular
diseases with varying degrees of success. The ROCK inhibitor Y27632 reduces
U46619 induced contraction in myometrial and placental arteries in normal term
pregnancies.60 We have quantified the expression on RHO proteins in paired placental
and myometrial samples.61 Placental RHO protein levels were up to three fold higher
than corresponding myometrial levels. RND3 proteins were differentially expressed
in primary, secondary and tertiary human placental trophoblasts.61 RND3 regulation
of normal placental development and its role in uterovascular diseases and placental
insufficiency need to be explored. Interestingly, although RND1, RND2 and RND3
mRNAs were expressed in the placental samples examined, we did not find any
evidence of RND1 or RND2 proteins. This suggests differences in transcriptional or
translational regulation of these GTP binding proteins between the human placenta
and myometrium.
CONCLUSION
The management of preterm labour is hampered by our poor understanding of the
mechanism of parturition in women and the lack of uterine specific drugs to control
myometrial contractility. In order to optimize tocolytic therapy in preterm labour, we
need to use agents that are effective between 23–30 weeks gestation, when neonatal
risk is high. Furthermore, these agents must be effective for a defined period of time
and ideally be given orally. RHO and ROCK inhibitors may fulfill these requirements
and urgent work is required to assess their efficacy in inhibiting spontaneous and
agonist- induced contractions in humans.
The role of RHO proteins in uterine function is complex and increased investigation
of their function will complement other approaches towards a better understanding
of the bio-endocrine pathways leading to labour.
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